Edition:
United States

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

2.75USD
1:00pm EDT
Change (% chg)

$-0.25 (-8.33%)
Prev Close
$3.00
Open
$3.14
Day's High
$3.14
Day's Low
$2.75
Volume
23,729
Avg. Vol
27,728
52-wk High
$20.40
52-wk Low
$2.55

Chart for

About

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery... (more)

Overall

Beta: 0.60
Market Cap(Mil.): $5.31
Shares Outstanding(Mil.): 1.77
Dividend: --
Yield (%): --

Financials

  CLRB.OQ Industry Sector
P/E (TTM): -- 28.29 30.45
EPS (TTM): -9.55 -- --
ROI: -177.43 12.92 12.63
ROE: -197.73 14.94 14.82

BRIEF-Cellectar Granted Orphan Drug Designation For CLR 131

* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage:

May 09 2018

BRIEF-Cellectar Biosciences Appoints Brian M. Posner As Chief Financial Officer

* CELLECTAR BIOSCIENCES APPOINTS BRIAN M. POSNER AS CHIEF FINANCIAL OFFICER

Apr 04 2018

BRIEF-Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles

* CELLECTAR GRANTED SEMINAL U.S. PATENT FOR PHOSPHOLIPID-ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 27 2018

BRIEF-Cellectar Reports 2017 Financial Results

* CELLECTAR REPORTS 2017 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

Mar 21 2018

BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma

* CELLECTAR BIOSCIENCES GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT NEUROBLASTOMA

Mar 19 2018

Earnings vs. Estimates